Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Fibrosarcoma - Overview
Fibrosarcoma - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Fibrosarcoma - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Fibrosarcoma - Companies Involved in Therapeutics Development
Advenchen Laboratories LLC
Alphamab Oncology
AntiCancer Inc
Apollomics Inc
AstraZeneca Plc
Bayer AG
BeiGene Ltd
Bicycle Therapeutics Plc
BioMed Valley Discoveries Inc
Calithera Biosciences Inc
F. Hoffmann-La Roche Ltd
Intezyne Inc
Lytix Biopharma AS
Mediolanum farmaceutici SpA
Orum Therapeutics Inc
Paranta Biosciences Ltd
Pharma Mar SA
Philogen SpA
PTC Therapeutics Inc
QBiotics Group Ltd
Shanghai Junshi Bioscience Co Ltd
Veltion Therapeutics LLC
Y-mAbs Therapeutics Inc
Fibrosarcoma - Drug Profiles
A-1R - Drug Profile
Product Description
Mechanism Of Action
History of Events
anlotinib hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
Antisense Oligonucleotides to Inhibit Rho-GAP for Colon Cancer and Fibrosarcoma - Drug Profile
Product Description
Mechanism Of Action
apatinib mesylate - Drug Profile
Product Description
Mechanism Of Action
History of Events
APL-502 - Drug Profile
Product Description
Mechanism Of Action
History of Events
AZD-1390 - Drug Profile
Product Description
Mechanism Of Action
AZD-7648 - Drug Profile
Product Description
Mechanism Of Action
BT-5528 - Drug Profile
Product Description
Mechanism Of Action
Cellular Immunotherapy for Oncology - Drug Profile
Product Description
Mechanism Of Action
CNV-NT - Drug Profile
Product Description
Mechanism Of Action
History of Events
daunorubicin hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
DP-02 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Drugs to Inhibit ATF4 for Oncology and Fibrosis - Drug Profile
Product Description
Mechanism Of Action
DTT - Drug Profile
Product Description
Mechanism Of Action
ecubectedin - Drug Profile
Product Description
Mechanism Of Action
History of Events
ELB-021 - Drug Profile
Product Description
Mechanism Of Action
History of Events
entrectinib - Drug Profile
Product Description
Mechanism Of Action
History of Events
envafolimab - Drug Profile
Product Description
Mechanism Of Action
History of Events
fibromun - Drug Profile
Product Description
Mechanism Of Action
History of Events
larotrectinib sulfate - Drug Profile
Product Description
Mechanism Of Action
History of Events
MEDI-5395 - Drug Profile
Product Description
Mechanism Of Action
History of Events
MI-130110 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Nivatrotamab - Drug Profile
Product Description
Mechanism Of Action
History of Events
pamiparib - Drug Profile
Product Description
Mechanism Of Action
History of Events
RT-11i - Drug Profile
Product Description
Mechanism Of Action
sapanisertib - Drug Profile
Product Description
Mechanism Of Action
History of Events
selitrectinib - Drug Profile
Product Description
Mechanism Of Action
History of Events
tigilanol tiglate - Drug Profile
Product Description
Mechanism Of Action
History of Events
toripalimab - Drug Profile
Product Description
Mechanism Of Action
History of Events
unesbulin - Drug Profile
Product Description
Mechanism Of Action
Fibrosarcoma - Dormant Projects
Fibrosarcoma - Product Development Milestones
Featured News & Press Releases
May 11, 2020: TRACON Pharmaceuticals announces successful type B meeting with FDA for pivotal study of envafolimab in sarcoma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Fibrosarcoma, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Fibrosarcoma, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Target, 2022 (Contd..1)
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Fibrosarcoma - Pipeline by Advenchen Laboratories LLC, 2022
Fibrosarcoma - Pipeline by Alphamab Oncology, 2022
Fibrosarcoma - Pipeline by AntiCancer Inc, 2022
Fibrosarcoma - Pipeline by Apollomics Inc, 2022
Fibrosarcoma - Pipeline by AstraZeneca Plc, 2022
Fibrosarcoma - Pipeline by Bayer AG, 2022
Fibrosarcoma - Pipeline by BeiGene Ltd, 2022
Fibrosarcoma - Pipeline by Bicycle Therapeutics Plc, 2022
Fibrosarcoma - Pipeline by BioMed Valley Discoveries Inc, 2022
Fibrosarcoma - Pipeline by Calithera Biosciences Inc, 2022
Fibrosarcoma - Pipeline by F. Hoffmann-La Roche Ltd, 2022
Fibrosarcoma - Pipeline by Intezyne Inc, 2022
Fibrosarcoma - Pipeline by Lytix Biopharma AS, 2022
Fibrosarcoma - Pipeline by Mediolanum farmaceutici SpA, 2022
Fibrosarcoma - Pipeline by Orum Therapeutics Inc, 2022
Fibrosarcoma - Pipeline by Paranta Biosciences Ltd, 2022
Fibrosarcoma - Pipeline by Pharma Mar SA, 2022
Fibrosarcoma - Pipeline by Philogen SpA, 2022
Fibrosarcoma - Pipeline by PTC Therapeutics Inc, 2022
Fibrosarcoma - Pipeline by QBiotics Group Ltd, 2022
Fibrosarcoma - Pipeline by Shanghai Junshi Bioscience Co Ltd, 2022
Fibrosarcoma - Pipeline by Veltion Therapeutics LLC, 2022
Fibrosarcoma - Pipeline by Y-mAbs Therapeutics Inc, 2022
Fibrosarcoma - Dormant Projects, 2022